Bacterial Endotoxin Test

What is Bacterial Endotoxin Testing?

The Bacterial Endotoxins Test (BET) is an in vitro assay for detection and quantitation of bacterial endotoxins, a component of the cell wall of gram-negative bacteria. The BET is performed as part of the lot release testing for medical devices with direct or indirect contact to the cardiovascular system, lymphatic system, or cerebrospinal fluid. Injectable pharmaceutical products must also be tested for bacterial endotoxins. Routine monitoring of water systems and incoming materials can help to ensure that the process does not contribute endotoxins to the final product.

Zexa Labs provides a Bacterial Endotoxins Test (BET), which is an in vitro assay for detection and quantitation of bacterial endotoxins, a component of the cell wall of Gram-negative bacteria. The BET is performed as part of the lot release testing for analysis. Injectable pharmaceutical products must also be tested for bacterial endotoxins. Routine monitoring of water systems and incoming materials can help to ensure that the process does not contribute endotoxins to the final product.

Specific to pharmaceutical manufacturers, Zexa Labs provides routine IP/USP and EP compendial tests for product sterility, bacterial endotoxin, particulate analysis, antibiotic potency assays (APA), antimicrobial preservative efficacy studies (APE) and microbial identification services. For nonsterile pharmaceutical products such as transdermal patches, we also offer routine microbial enumeration studies for objectionable organisms (USP 61/62).

This assay is also known as the Limulus Amebocyte Lysate (LAL) test and is sometimes referred to as the pyrogen test (because bacterial endotoxins can cause a fever in mammals, including humans). However, the BET should not be confused with the rabbit pyrogen test described in USP chapter <151>.

Why choose Zexa Labs to perform BET?

Zexa Labs is an industry leader in bacterial endotoxins testing. We can provide test results the day after the sample receipt. For routine testing, results are typically completed within four business day following sample receipt. Our validations and method development studies are done thoroughly with a process that has been proven effective and compliant. We are happy to help resolve any questions you may have about the test criteria, and can also help with failure investigations and evaluation of the manufacturing process.

All testing meets the requirements outlined in IP general Chapters, USP chapter <85>, USP chapter <161>, ANSI/AAMI ST72:2011, EP 2.6.14, JP 4.01.

Study Outline

The Bacterial Endotoxins test can be performed by the kinetic turbidimetric, kinetic chromogenic, or gel-clot test methods. However, the kinetic test methods have significant advantages over the gel-clot test.

Sample extractions: Device extractions are performed using water free of detectable endotoxins. The extraction process involves flushing and/or washing the devices with the minimum amount of liquid to properly extract the device. Devices with a non-pyrogenic fluid pathway are extracted by flushing the relevant fluid pathway with extraction liquid that has been heated to 37 ± 1°C and maintaining contact for not less than one hour. Device immersions are performed by washing the devices in extraction liquid at 37 – 40°C for >60 minutes with intermittent swirling on an orbital shaker.

Test procedure: A BET involves analyzing the liquid sample or sample extract using Limulus Amebocyte Lysate (LAL). LAL is a reagent made from the blood of the horseshoe crab. In the presence of bacterial endotoxins, the lysate reacts to form a clot or cause a color change depending on the technique. The test sample is compared to a standard curve made from known endotoxin concentrations. All tests are performed in at least duplicate. A positive product control and negative control are included as part of each assay.

Validation: It is required to demonstrate that the test sample does not interfere with the ability to detect endotoxins. This is accomplished with the positive product control (also called the spike recovery) for the kinetic test methods, and with a separate inhibition and enhancement assay for the gel-clot method.

Samples that require a treatment such as reconstitution in a solvent other than water, heat denaturing, centrifugation, or filtration should be validated to demonstrate that the treatment does not result in the loss of endotoxins. This is accomplished by inoculating the sample with endotoxins and subjecting the inoculated sample to the chosen treatment.

The endotoxin limit for medical devices is not more than 20.0 EU/device unless the device will have contact with cerebrospinal fluid, in which case the limit is 2.15 EU/device. Ophthalmic implants and OVDs may be required to meet a lower limit of 0.2 EU/device or 0.2 EU/mL. Endotoxin limits for pharmaceutical products are based on the maximum dose that can be administered in a 1-hour time period.

Contact Us
If you have additional questions about pharmaceutical testing or would like to consult with experts at Zexa Labs, just send us a request or call us at + 0179 545 6944.

Testing Options
Ask an expert for a specific consultation on your product. If you are ready to submit your samples for testing, fill out the Sample Submission Form.